MYGN stock news · Myriad Genetics, Inc.
Get alerts for MYGN
Follow Myriad Genetics, Inc. (MYGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MYGNPiper Sandler changed Myriad Genetics' rating to Neutral.
NeutralMyriad Genetics received a rating change from Underweight to Neutral, and Piper Sandler set a $5 target. The improved view remains cautious and brings no news about the company's business.
On Tuesday, 12 health care stocks saw big price changes during the day.
NeutralMyriad Genetics shares rose about 37% to $5.76, but this report gives no business news to explain the move. It does not change the company's outlook.
Myriad Genetics has agreed to sell its prenatal health business to LabCorp for $210 million.
NeutralMyriad agreed to sell its prenatal testing business for $210 million in cash plus inventory value. It would also give up those products, and the filing does not show enough to change the company's outlook.
Myriad Genetics says some directors and officers are leaving, while new ones are being chosen and hired.
Bad for MYGNMyriad Genetics agreed to pay former commercial chief Brian Donnelly $1.3 million and speed up some share awards. Those added costs weigh against the company, though his departure was already known.
On Thursday evening, 12 health care stocks changed a lot in price.
NeutralMyriad Genetics shares fell 9.32% to $3.75 after hours, but the article gives no company reason for the fall, so it does not change the company's outlook.
Myriad Genetics says some directors and officers are leaving, while new ones are being hired.
NeutralMyriad promoted an internal product leader to commercial while the departing CCO will help transition; this routine personnel change leaves the company's outlook unchanged.
Tuesday's pre-market session sees Cango, Nio, and several major stocks experiencing declines.
NeutralPre-market share weakness was reported but no company-specific fundamental details were provided to infer a clear directional impact.